Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 223


Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9. Epub 2001 Aug 14.


Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.

Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W, Lichtenstein A.

Cancer Res. 2002 Sep 1;62(17):5027-34.


Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.

Xu G, Zhang W, Bertram P, Zheng XF, McLeod H.

Int J Oncol. 2004 Apr;24(4):893-900.


Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.

Grünwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M.

Cancer Res. 2002 Nov 1;62(21):6141-5.


An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.

Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, Hedrick-Ellenson L, Parsons R.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10320-5. Epub 2001 Aug 14.


A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.

Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, Donner DB.

Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4640-5. Epub 2001 Apr 3.


Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.

Pene F, Claessens YE, Muller O, Viguié F, Mayeux P, Dreyfus F, Lacombe C, Bouscary D.

Oncogene. 2002 Sep 26;21(43):6587-97.


Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.

Clin Cancer Res. 2004 Dec 1;10(23):8059-67.


FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation.

Shah SA, Potter MW, Ricciardi R, Perugini RA, Callery MP.

J Surg Res. 2001 May 15;97(2):123-30.


Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.

DeGraffenried LA, Fulcher L, Friedrichs WE, Grünwald V, Ray RB, Hidalgo M.

Ann Oncol. 2004 Oct;15(10):1510-6.


Loss of PTEN expression leading to high Akt activation in human multiple myelomas.

Hyun T, Yam A, Pece S, Xie X, Zhang J, Miki T, Gutkind JS, Li W.

Blood. 2000 Nov 15;96(10):3560-8.


Assessment of cell-signaling pathways in the regulation of mammalian target of rapamycin (mTOR) by amino acids in rat adipocytes.

Pham PT, Heydrick SJ, Fox HL, Kimball SR, Jefferson LS Jr, Lynch CJ.

J Cell Biochem. 2000 Sep 7;79(3):427-41.


Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism.

Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J.

J Biol Chem. 1998 Jun 5;273(23):14484-94. Erratum in: J Biol Chem 1998 Aug 21;273(34):22160.


mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma.

Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, Holland EC.

Neoplasia. 2005 Apr;7(4):356-68.


Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy.

Nagai K, Matsubara T, Mima A, Sumi E, Kanamori H, Iehara N, Fukatsu A, Yanagita M, Nakano T, Ishimoto Y, Kita T, Doi T, Arai H.

Kidney Int. 2005 Aug;68(2):552-61.


Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN.

Mourani PM, Garl PJ, Wenzlau JM, Carpenter TC, Stenmark KR, Weiser-Evans MC.

Circulation. 2004 Mar 16;109(10):1299-306. Epub 2004 Mar 1.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk